The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models

@article{Deleu2009TheEO,
  title={The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models},
  author={Sarah Deleu and Miguel Lemaire and Janine Arts and Eline Menu and Els Van Valckenborgh and Peter J. H. King and Isabelle Vande Broek and Hendrik R. De Raeve and Ben Van Camp and Peter Croucher and Karin Vanderkerken},
  journal={Leukemia},
  year={2009},
  volume={23},
  pages={1894-1903}
}
Multiple myeloma (MM) is a B-cell malignancy, which often remains incurable because of the development of drug resistance governed by the bone marrow (BM) microenvironment. Novel treatment strategies are therefore urgently needed. In this study, we evaluated the anti-MM activity of JNJ-26481585, a novel ‘second-generation’ pyrimidyl-hydroxamic acid-based histone deacetylase inhibitor, using the syngeneic murine 5TMM model of MM. In vitro, JNJ-26481585 induced caspase cascade activation and… CONTINUE READING